Lipigon Pharmaceuticals AB (publ)

DB:9RP Stock Report

Market Cap: €2.2m

Lipigon Pharmaceuticals Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

DB:9RP Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
03 Dec 24Buy€6,587Stefan NilssonIndividual437,479€0.017
10 Sep 24Buy€6,558Stefan NilssonIndividual313,425€0.021
17 Jun 24Buy€3,454Stefan NilssonIndividual136,056€0.025
19 Apr 24Buy€8,704Stefan NilssonIndividual300,852€0.029

Insider Trading Volume

Insider Buying: 9RP insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of 9RP?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders4,510,4403.04%
Private Companies14,705,8379.91%
Institutions37,997,09425.6%
General Public91,117,14761.4%

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 17.3%.

Top Shareholders

Top 19 shareholders own 38.57% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
8.68%
Nordnet Pensionsförsäkring Ab, Asset Management Arm
12,870,253€189.9k0%0.04%
6.18%
Avanza Fonder AB
9,160,215€135.2k0%no data
4.13%
Rekonstructa AB
6,125,005€90.4k0%no data
3.75%
Ålandsbanken Asset Management Ab
5,568,171€82.2k0%0.08%
3.03%
Magbaleo AB, Asset Management Arm
4,500,000€66.4k0%no data
2.48%
Fort Knox FÖRvaring Ab
3,679,218€54.3k0%no data
2.36%
Handelsbanken Asset Management
3,501,980€51.7k0%no data
1.79%
Stefan Nilsson
2,658,805€39.2k19.7%no data
1.78%
Rjan Holding AB
2,646,880€39.1k0%no data
1.61%
Falvir AB
2,394,074€35.3k0%100.0%
1.52%
Tuvedalen Limited
2,254,734€33.3k0%no data
0.61%
Eva Lindqvist
900,000€13.3k0%no data
0.23%
Lars Öhman
343,200€5.1k0%no data
0.13%
Johannes Hulthe
199,998€3.0k0%no data
0.11%
Jessica Martinsson
165,000€2.4k0%no data
0.076%
Stefan Pierrou
113,437€1.7k0%no data
0.067%
Hugo Petit
100,000€1.5k0%no data
0.02%
David Westberg
30,000€442.80%no data
0.0016%
FCG Fonder AB
2,401€35.50%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/02 09:21
End of Day Share Price 2025/01/31 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Lipigon Pharmaceuticals AB (publ) is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Carl RamaniusRedeye